Adeno-associated variants, formulations and methods for pulmonary delivery
The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.
1. A recombinant adeno-associated virus (rAAV) comprising (i) a capsid comprising a capsid protein of SEQ ID NO:12 and (ii) a heterologous nucleic acid comprising from 5′ to 3′: (a) an AAV2 terminal repeat (b) a promoter (c) a nucleotide sequence encoding a biologically active truncated cystic fibrosis transmembrane conductance regulator (CFTR) protein lacking amino acids 708-759 of the human CFTR protein sequence (d) a polyadenylation sequence and (e) an AAV2 terminal repeat, wherein the nucleotide sequence encoding said biologically active truncated CFTR protein lacking amino acids 708-759 of the human CFTR protein sequence is at least 95% identical to the nucleotide sequence set forth as SEQ ID NO:43.
2. The rAAV according to claim 1 , wherein the nucleotide sequence encoding said biologically active truncated CFTR protein comprises the nucleotide sequence set forth as SEQ ID NO:43.
3. The rAAV according to claim 1 , wherein the heterologous nucleic acid comprises a nucleotide sequence at least 95% identical to the nucleotide sequence set forth as SEQ ID NO:45.
4. The RAAV vector according to claim 3 , wherein the heterologous nucleic acid comprises the nucleotide sequence set forth as SEQ ID NO:45.
5. The rAAV according to claim 1 , wherein the promoter is a constitutive promoter.
6. The rAAV according to claim 1 , wherein the promoter is a tissue specific promoter that directs preferential expression of the nucleic acid in a lung cell.
7. The rAAV according to claim 2 , wherein the promoter is a CMV173 promoter and is operably linked to the nucleotide sequence encoding said biologically active truncated CFTR protein.
8. The rAAV according to claim 7 , wherein the CMV173 promoter has the sequence set forth as SEQ ID NO:44.
9. A pharmaceutical composition comprising the rAAV according to claim 1 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the rAAV according to claim 4 and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition according to claim 9 , comprising between 10 11 to 10 14 vector genomes (vg) per ml.
12. The pharmaceutical composition according to claim 11 , wherein the pharmaceutical composition is in the form of a liquid/suspension suitable for aerosolized delivery or is formulated as an aerosol and/or is an inhaled dosage form.